BETA: Please send your feedback!
Med BioGene
MBI-CA:TSX
Biotechnology
—
MICRO cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
About
Biotechnology
Founded 2006
Med BioGene, Inc. operates as a life science company, which engages in the development and commercialization of genomic-based clinical laboratory diagnostic tests. It focuses on managing the license and rights to GeneFx Lung, a proprietary gene expression-based test for early-stage non-small-cell lung cancer. The company was founded on April 28, 2006 and is headquartered in Vancouver, Canada.
website
Headquarters
Executives
Name | Title | Gender |
Iain Weir-Jones, PhD | Chairman & Chief Executive Officer | Male |
Ibrahim Ghobrial | Chief Financial Officer | Male |
Mindful Investing Summary
Med BioGene - Competitors and Related Companies
How Med BioGene stacks up to its peers in the Biotechnology industry or with competing business segments.
Med BioGene
MBI-CA:TSX
Biotechnology
—
MICRO cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Loading…